Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Velocity-Based Resistance Training Effects on Inflammation in Older Adults

4 mei 2026 bijgewerkt door: National Taipei University

Dose-Response Effects of Velocity-Based Resistance Training on Anti-Inflammatory Responses in Older Adults

This study aims to investigate the effects of resistance training (RT) with different training volumes on immune modulation and anti-inflammatory responses in older adults. Participants will be randomly assigned to one of three RT volume groups (low, medium, or high) or a non-exercise control group. Participants in the training groups will complete a 4-week RT program, followed by a 4-week detraining phase. The findings are expected to provide evidence for volume-specific RT prescriptions to support healthy aging.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

60

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

  • Taiwan
      • Taipei, Taiwan, 116
        • Werving
        • National Taiwan Normal University
        • Contact:
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Ja

Beschrijving

Inclusion Criteria:

  • Aged 60-75 years or older
  • No regular resistance training habit (defined as ≥2 sessions per week) in the past year
  • No musculoskeletal injuries within the past six months

Exclusion Criteria:

  • Obesity (BMI > 30 kg/m²), diabetes, hypertension, cancer, heart, kidney, or liver disease, or any other condition that may influence study outcomes.
  • Regular use of anti-inflammatory medications (e.g., NSAIDs).
  • Smoking or alcohol abuse
  • Inability to safely perform the prescribed resistance exercise movements
  • Unable to fully comprehend the study information and instructions.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: low training volume resistance exercise
Participants assigned to the low-volume resistance training group will perform one set per exercise at a load corresponding to 80% of 1RM. Each set will be terminated when movement velocity decreases by 30% from the first repetition. Rest intervals of 2-3 minutes will be provided between exercises.
Ander: Resistance exercise
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions. All sessions will be supervised by research personnel to ensure proper technique and safety. Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
Experimenteel: medium training volume resistance exercise
Participants assigned to the medium-volume resistance training group will perform three sets per exercise at 80% of 1RM. Each set will be terminated when movement velocity decreases by 30% relative to the first repetition. Rest intervals of 90 seconds will be provided between sets, and 2-3 minutes between exercises.
Ander: Resistance exercise
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions. All sessions will be supervised by research personnel to ensure proper technique and safety. Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
Experimenteel: high training volume resistance exercise
Participants assigned to the high-volume resistance training group will perform five sets per exercise at 80% of 1RM. Each set will be terminated when movement velocity decreases by 30% relative to the first repetition. Rest intervals of 90 seconds will be provided between sets, and 2-3 minutes between exercises.
Ander: Resistance exercise
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions. All sessions will be supervised by research personnel to ensure proper technique and safety. Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
Geen tussenkomst: sedentary control
Participants in control trial stayed sedentary during the period.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Changes in IL-6 concentration
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Plasma IL-6 concentrations will be measured and reported in pg/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in soluble IL-6 receptor concentration
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Soluble IL-6 receptor concentrations will be measured and reported in ng/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in soluble gp130 concentration
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Soluble gp130 concentrations will be measured and reported in ng/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in IL-10 concentration
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
IL-10 concentrations will be measured and reported in pg/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in IL-1RA concentration
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
IL-1RA concentrations will be measured and reported in pg/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in TNF-α concentration
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
TNF-α concentrations will be measured and reported in pg/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Borgs Ratings of Perceived Exertion (RPE)
Tijdsspanne: 1-hour during each exercise intervention
Borgs RPE is a method of estimating exertion rating, based on a 1 to 10 rating scale (1 being the no exertion at all, 10 being maximal exertion).
1-hour during each exercise intervention
Handgrip strength
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Maximal handgrip strength will be assessed using a digital hand dynamometer and reported in kilograms.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Knee extension strength
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Maximal voluntary isometric and isokinetic concentric knee extension strength of the dominant leg will be assessed using an isokinetic dynamometer and reported in Newton-meters.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
30-second chair-stand test
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Lower-body functional capacity will be assessed by the number of repetitions completed during a 30-second chair-stand test.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Single-leg balance test
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Balance performance will be assessed as the duration of single-leg stance and reported in seconds.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Timed up and go test
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Functional mobility will be assessed using the Timed Up and Go test, with performance quantified as the time (seconds) required to stand up from a seated position, walk 3 meters, turn, walk back, and sit down.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in SHIP1 protein expression in peripheral blood mononuclear cells (PBMCs)
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular SHIP1 protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in gp130 (CD130) protein expression in PBMCs
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular gp130 (CD130) protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in STAT3 protein expression in PBMCs
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular STAT3 protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in phosphorylated STAT3 protein expression in PBMCs
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular phosphorylated STAT3 (p-STAT3) protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in IL-6 receptor alpha (CD126) protein expression in PBMCs
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular IL-6 receptor alpha (CD126) protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in Beta-2 adrenergic receptor (β2-AR) protein expression in PBMCs
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular β2-adrenergic receptor (β2-AR) protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in SOCS3 protein expression in PBMCs
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular SOCS3 protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in white blood cell count
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Total white blood cell count will be measured and reported in cells/μL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in lymphocyte count
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Lymphocyte count will be measured and reported in cells/μL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in neutrophil count
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Neutrophil count will be measured and reported in cells/μL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in monocyte count
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Monocyte count will be measured and reported in cells/μL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Body fat percentage
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Body fat percentage will be measured using a body composition analyzer and reported as a percentage.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Lean body mass
Tijdsspanne: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Total lean body mass will be measured using a body composition analyzer and reported in kilograms.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

National Taipei University

Onderzoekers

  • Hoofdonderzoeker: Shun-Hsi Tsai, Ph.D., National Taipei University

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

20 april 2026

Primaire voltooiing (Geschat)

1 maart 2029

Studie voltooiing (Geschat)

1 december 2029

Studieregistratiedata

Eerst ingediend

15 april 2026

Eerst ingediend dat voldeed aan de QC-criteria

28 april 2026

Eerst geplaatst (Werkelijk)

5 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

8 mei 2026

Laatste update ingediend die voldeed aan QC-criteria

4 mei 2026

Laatst geverifieerd

1 april 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • ECKIRB1140803

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Klinische onderzoeken op Ontstekingsreactie

Zoek naar vergelijkbare onderzoeken

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

CROs by country

CROs in Cambodia

Voorwaarden

Zeldzame ziekten

Geneesmiddelinterventies

Voedingssupplementen

Sponsor / medewerkers

Locaties

Abonneren